Recent developments include quarterly earnings reports, executive appointments, and corporate governance events.

• BioLargo reported quarterly earnings results in March 2025, providing updated financial performance data [N1].
• CEO Dennis Calvert was appointed to the Department of Commerce’s Emerging Technologies and Technical Advisory Committee (ETTAC) in December 2024 [N2].
• BioLargo scheduled its annual meeting for June 2024, indicating ongoing corporate governance activities [N3].

BioLargo’s diversified technology portfolio, including patented odor control products, innovative battery technology with potential advantages in safety and longevity, and FDA-cleared medical products, provides multiple avenues for growth. Strategic partnerships and joint ventures, especially in battery manufacturing, could enable scaling without heavy capital expenditure. The company’s intellectual property and ongoing R&D investments support potential competitive differentiation. Recent executive appointments and capital raises indicate active management and resource mobilization.

BioLargo faces liquidity constraints with current assets only marginally exceeding current liabilities, raising going concern questions. Significant customer concentration exposes revenue and receivables to risk, as evidenced by the default and litigation involving a key partner. The company’s technologies, while promising, require further commercialization and capital investment, which may be challenging. The competitive landscape for battery and medical products is intense, and the company’s limited scale and resources may hinder market penetration and profitability.

BioLargo’s moat is based on its proprietary technologies protected by a portfolio of 34 patents and trade secrets, spanning odor control, battery technology, and medical products. Its Cellinity™ battery technology claims unique safety and performance advantages over lithium-ion batteries, supported by third-party validation. The company’s partially owned subsidiaries and strategic partnerships provide diversified market access. However, the moat is challenged by the need for capital to scale production and commercialize technologies, and by customer concentration risks.

• Liquidity Risk: Current assets and cash balances are only slightly above current liabilities, with management expressing substantial doubt about the company’s ability to continue as a going concern without additional financing or increased revenues.
• Customer Concentration Risk: A single customer accounts for a large portion of revenues and accounts receivable, with some receivables converted to a note receivable due to payment issues, increasing credit risk and revenue volatility.
• Commercialization Risk: Key technologies such as the Cellinity™ battery and medical products require further development, manufacturing scale-up, and market acceptance, which depend on successful partnerships and capital availability.
• Intellectual Property Risk: While the company holds patents and trade secrets, ongoing protection and enforcement are critical, especially given litigation related to technology licensing and potential competition.

• BioLargo, Inc. operates through multiple wholly and partially owned subsidiaries including BioLargo Life Technologies, ONM Environmental, BioLargo Energy Technologies, BioLargo Canada, BioLargo Engineering Science & Technologies, BioLargo Equipment Solutions & Technologies, BioLargo Development Corp., and Clyra Medical Technologies.
• The company’s subsidiaries focus on diverse markets: odor and VOC control products (ONM Environmental), proprietary battery technology (BioLargo Energy Technologies, BETI), water treatment products, engineering services, and medical/dental products (Clyra Medical).
• BETI develops Cellinity™, a novel liquid sodium battery technology for long-duration energy storage with claimed advantages over lithium-ion batteries including safety, sustainability, and longevity.
• Clyra Medical Technologies develops wound and skin infection treatment products based on patented Copper-Iodine Complex Solution technology, with FDA 510(k) clearance for its first product ViaCLYR™.
• ONM Environmental sells odor-control products including private-label pet odor products; a key partner Pooph Inc. defaulted on payments leading to license revocation and litigation.
• BioLargo holds 34 patents (26 in the US) with an average remaining duration of seven years, and relies on trade secrets and technical know-how for intellectual property protection.
• The company’s common stock trades on OTCQX under ticker BLGO.
• As of December 31, 2025, BioLargo had cash and cash equivalents of $3.883 million, current assets of $5.114 million, current liabilities of $5.063 million, resulting in a current ratio of 1.01 and a cash ratio of 0.77.
• Revenue for the year ended December 31, 2023 was $12.23 million.
• Basic earnings per share for the year ended December 31, 2025 was -$0.04.
• The company’s CEO and board oversee cybersecurity risk management, supported by managed service providers with expertise in cybersecurity.
• BioLargo’s liquidity and capital resources show ongoing needs for investment capital to fund operations and technology development, with substantial doubt about going concern unless revenues or financing improve.
• The company has engaged in equity sales to Lincoln Park Capital Fund LLC, raising proceeds but not intending to renew the purchase agreement.
• Customer concentration is significant, with one customer accounting for over 50% of revenues and a large portion of accounts receivable, some of which was converted to a note receivable.
• The company’s subsidiaries include partially owned entities BETI, BLEST, and Clyra Medical, consolidated in financial statements.
• Recent news includes quarterly earnings reports, CEO appointment to Department of Commerce’s ETTAC, and scheduling of annual meeting in June 2024.